ZCZheng-He Chen

Zheng-He Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zheng-He Chen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Xiang-Heng Zhang

    Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China

    4 shared publications
  • Fuhua Lin

    Department of Neurosurgery and Neuro-Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

    3 shared publications
  • Yonggao Mou

    Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China

    3 shared publications
  • Hao Duan

    Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

    2 shared publications
  • Jian Wang

    Department of Neurosurgery and Neuro-Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

    2 shared publications
  • Zhenqiang He

    Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

    2 shared publications

Latest Publications

  • Open Access

    The application of fluorescein sodium for the resection of medulloblastoma

    by Zheng-He Chen, Xiang-Heng Zhang, Fu-Hua Lin, Chang Li, Jie-Tian Jin, Zhi-Huan Zhou, Si-Han Zhu, Zhu-Qing Cheng, Sheng Zhong, Zhen-Qiang He, et al.

    Introduction: Surgical resection of medulloblastoma (MB) remains a challenge. At present, a variety of tracers have been used for intraoperative tumor visualization. However, there are few reports on the intraoperative visualization of MB. Hence, we reported our experience of applying fluorescein sodium (FS) in MB surgery. Methods: We retrospectively analyzed the clinical information of patients with MB confirmed by surgery and pathology from January 2016 to December 2020 from Sun Yat-sen University Cancer Center. A total of 62 patients were enrolled, of which 27 received intraoperative FS and 35 did not. The intraoperative dose of FS was 3 mg/kg. Results: Among the 62 patients, 42 were males, and twenty were females. The age of onset in the FS group was 9.588 ± 7.322, which in the non-fluorescein sodium group was 13.469 ± 10.968, p = 0.198. We did not find significant differences in tumor location, tumor size, tumor resection, tumor histology, and preoperative symptoms (hydrocephalus, headache, vomit, balance disorder) between the groups. There was no significant difference in the postoperative symptoms (hydrocephalus, headache, vomiting, balance disorder, and cerebellar mutism). However, patients in the FS group had a relatively low incidence of balance disorder and cerebellar mutism. There was definite fluorescence of tumor in all cases of the FS group, and even the tiny metastatic lesion was visible. No case had side effects related to the use of FS. Conclusions: FS is safe and effective in MB surgery. Whether the application of FS for surgery can reduce complications remains to be studied in the future.


  • Open Access

    Computational study on novel natural inhibitors targeting BCL2

    by Xiaye Lv, Yuting Jiang, Xinhui Wang, HaoQun Xie, Gaojing Dou, Jing Wang, Wenzhuo Yang, Hongyu Wang, Zijian Li, Xiangheng Zhang, et al.

    Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for diffuse large B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided virtual screening. Libdock was applied to 17,931 compounds and the top 20 were selected for further analysis. Selected compounds were performed absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the selected ligands and BCL2 was confirmed by Molecular docking. The new natural compounds, ZINC00000255131 and ZINC00013298233, were found to bind closely with BCL2. Furthermore, they all scored lower in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation shows that the combinations of ZINC00000255131 and ZINC00013298233 with BCL2 in the natural environment are more stable. Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. These compounds have been proved to be safe, which is of great significance for the development and improvement of DLCBL drugs.


  • Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma

    by Jue-Hui Li, Zhen-Qiang He, Fu-Hua Lin, Zheng-He Chen, Shi-Yu Yang, Hao Duan, Xiao-Bing Jiang, Fuad Al-Nahari, Xiang-Heng Zhang, Jiang-Huang Wang, et al.


  • Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas

    by Ke Sai, Ming-Gu Zhong, Jian Wang, Yin-Sheng Chen, Yong-Gao Mou, Chao Ke, Xiang-Heng Zhang, Qun-Ying Yang, Fu-Hua Lin, Cheng-Cheng Guo, et al.